Brief: Actinium Presents Positive Findings From Mid-Point Analysis Of Pivotal Sierra Trial Of Iomab-B At 2020 Transplantation & Cellular Therapy Meetings Of ASTCT And CIBMTR

Actinium Pharmaceuticals

21/02/2020 12:41

Feb 21 (Reuters) - Actinium Pharmaceuticals Inc  ATNM.A :
    * ACTINIUM PRESENTS POSITIVE FINDINGS FROM MID-POINT
ANALYSIS OF
PIVOTAL SIERRA TRIAL OF IOMAB-B AT 2020 TRANSPLANTATION &
CELLULAR THERAPY MEETINGS OF ASTCT AND CIBMTR (TCT)
    * ACTINIUM PHARMACEUTICALS - 78% OF PATIENTS IN IOMAB-B ARM
ARE
POTENTIALLY EVALUABLE FOR PRIMARY ENDPOINT COMPARED TO 13
PERCENT IN CONTROL ARM
    * ACTINIUM- SUBSTANTIALLY LOWER RATES OF FEBRILE
NEUTROPENIA,
SEPSIS IN PATIENTS RECEIVING IOMAB-B VERSUS THOSE GETTING
SALVAGE CHEMOTHERAPY IN CONTROL ARM
    * ACTINIUM - PROTOCOL AMENDMENT ALLOWING PATIENTS FAILING
VENETOCLAX INDUCTION THERAPY TO ENROLL IN SIERRA TRIAL EXPECTED
TO RAISE ELIGIBLE PATIENT POOL

Source text for Eikon:  ID:nPn9jBxTFa 
Further company coverage:  ATNM.A 

 ((Reuters.Briefs@thomsonreuters.com;))